Thermo Fisher Scientific has extended its state-of-the-art manufacturing capability in Shanghai, China, for the production of Thermo Scientific Nunc Cell Factory single-use, certified-sterile bioprocessing systems.
The Shanghai facility complements the Nunc Cell Factory production sites in Rochester, New York, and Roskilde, Denmark. The expansion forms part of a continuing strategy of global investment in the regional production of its bioprocessing products to support the local bioproduction of vaccines, cell and protein therapeutics.
‘The Rochester, Roskilde and Shanghai sites are designed to meet local and international demands both now and in the future, and will facilitate the effective streamlining and continuity of supply for our growing customer base,’ said Chuck Kummeth, president of the laboratory consumables division of Thermo Fisher Scientific.
‘Our aim is to provide regional biopharma production sites with the fastest and most efficient delivery of cell culture consumables, and to enable us to do this, we are currently investing heavily in the APAC region in particular.’
Stringent quality control procedures are in place across all the global sites to guarantee the consistent delivery of high quality products. ‘Product quality is paramount, and the provision of cell culture platforms and containment systems that are specifically developed to facilitate easy scale-up and commercialisation of bioproduction processes have been key to our success so far,’ Kummeth added.
Thermo Scientific’s bioprocessing products portfolio is complemented by media supplements, process liquids and cell culture sera, and the extended production facilities in Shanghai follow a recently opened site in Beijing dedicated to the hydration of cell culture media, and a joint venture in Lanzhou, China, for the collection, processing and selling of serum into local markets.